Ono Gets Its Hands on Equillium’s Rights to 1st-in-Class CD6 Drug

Ono Pharmaceutical said on December 6 that it has struck an exclusive option and asset purchase deal with California-based Equillium for the US firm’s rights to itolizumab, a first-in-class anti-CD6 monoclonal antibody. Under the deal, Equillium will be eligible for...read more